Portage BiotechPRTG
PRTG
About: Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
Employees: 7
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
41% more capital invested
Capital invested by funds: $558K [Q2] → $788K (+$230K) [Q3]
1.11% more ownership
Funds ownership: 11.34% [Q2] → 12.45% (+1.11%) [Q3]
36% less funds holding
Funds holding: 22 [Q2] → 14 (-8) [Q3]
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 10
Research analyst outlook
We haven’t received any recent analyst ratings for PRTG.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
No impact at this time on the listing of the Company's Ordinary Shares on Nasdaq Company intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, announced today that it received written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) on December 10, 2024 indicating that the Company was not in compliance with the minimum shareholders' equity requirement for continued listing on The Nasdaq Capital Market (the “Capital Market”) as set forth in Nasdaq Listing Rule 5550(b)(1) (the “Shareholders' Equity Requirement”), because the Company's shareholders' equity of $695,000 as of September 30, 2024, as reported in the Company's Report on Form 6-K containing unaudited condensed consolidated interim financial statements for the three and six months ended September 30, 2024, filed with the United States Securities and Exchange Commission (the “SEC”) on November 26, 2024, was below the required minimum of $2.5 million, and because, as of the date of the Notice (and as of the date of this press release), the Company did not meet either of the alternative continued listing standards for the Capital Market, relating to market value of listed securities of at least $35 million or net income from continuing operations of at least $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.
Neutral
GlobeNewsWire
3 weeks ago
Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
WESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal quarter ended September 30, 2024.
Neutral
GlobeNewsWire
8 months ago
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.
Neutral
GlobeNewsWire
8 months ago
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Company generated approximately $2.8M of non-dilutive funding to extend cash runway Company generated approximately $2.8M of non-dilutive funding to extend cash runway
Neutral
GlobeNewsWire
9 months ago
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update Company focused on adenosine platform clinical development
Neutral
GlobeNewsWire
11 months ago
Portage Biotech Reports Business and Strategic Update
WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced the outcome from the company's comprehensive review of its pipeline in the context of the current capital raising market conditions.
Neutral
GlobeNewsWire
1 year ago
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended September 30, 2023.
Charts implemented using Lightweight Charts™